AstraZeneca and C4X Discovery Ink $402M COPD Collaboration | BioSpace

Retrieved on: 2022-11-28 21:29:09

Tags for this article:

Medicine

Health

Clinical medicine

Respiratory therapy

Respimat

Chronic obstructive pulmonary disease

Obstructive lung disease

Long-acting beta-adrenoceptor agonist

Click the tags to see associated articles and topics

AstraZeneca and C4X Discovery Ink $402M COPD Collaboration | BioSpace. View article details on HISWAI: https://www.biospace.com/article/astrazeneca-and-c4x-discovery-ink-402-million-copd-collaboration/

Excerpt

C4X entered into a licensing deal with AstraZeneca to develop an oral treatment for COPD and other inflammatory and respiratory illnesses that ...

Article found on: www.biospace.com

View Original Article